Supplemental Materials for Stein Gold et al. A Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Supplemental Material, PRISMA_NMA_Checklist - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, PRISMA_NMA_Checklist for Guselkumab for the Treatment of Moderate-to-Severe P...

Supplementary Material for: Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions

Gerdes S. (4906354)
Krakor M. (4906348)
Anger T. (4906357)
Hutt H.J. (4906351)
Körber A. (4473115)

March 2018

Background/Aims: To assess the efficacy and tolerability of the new aerosol foam of ca...

Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.

Kerkhof, P.C.M. van de
Peuter, R. de
Ryttov, J.
Jansen, J.P.

January 2011

Item does not contain fulltextOBJECTIVE: The efficacy of the two-compound formulation (TCF) product ...

Supplemental Materials for Stein Gold et al. A Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Stein Gold, L

Mendeley Supplemental Tables and Figures for Stein Gold et al. A Phase 2b, Randomized Clinical Trial...

Supplemental Materials for Stein Gold et al. A Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Stein Gold, L (via Mendeley Data)

May 2020

Mendeley Supplemental Tables and Figures for Stein Gold et al. A Phase IIb, Randomized Clinical Tria...

Secondary Efficacy Outcomes from a Phase 2b, Randomized Dose-Finding Study of Tapinarof Cream for the Treatment of Plaque Psoriasis

Stein Gold, Linda F
Bhatia, N
Tallman, A M
Rubenstein, D

August 2019

Introduction: Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under inv...

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients with Mild to Moderate Plaque Psoriasis: Results of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial. J Am Acad Dermatol. 2021.

Stein Gold, L

Mendeley Supplemental Figures and Table for Stein Gold et al. Efficacy and Safety of Apremilast in P...

34613 Tapinarof cream 1% once daily (QD) for plaque psoriasis: Secondary efficacy outcomes from a long-term extension (LTE) trial

Stein Gold, Linda F
Ehst, Benjamin
Ferris, Laura K
Brown, Philip M
Rubenstein, David S
Tallman, Anna M
Bagel, Jerry

September 2022

Background: Tapinarof cream 1% QD was efficacious and well tolerated versus vehicle in adults with m...

Supplementary Appendix - Efficacy and Patient-Reported Outcomes from a Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis

Paller, A (via Mendeley Data)

August 2020

Mendeley Supplemental Tables and Figures for Paller A, et al. Efficacy and Patient-Reported Outcomes...

SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial

Strober, B

Supplementary materials for the publication of Strober B. Deucravacitinib versus placebo and apremil...

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials

Desai, Seemal R
Stein Gold, Linda F
Cameron, Michael C
Golant, Alexandra
Lewitt, G. Michael
Bruno, Matthew J
Martin, George
Brown, Philip M
Rubenstein, David S
Butners, Victoria
Tallman, Anna M

October 2023

Tapinarof cream 1% (VTAMA(®); Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbo...

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...

Lebwohl, Mark (2020), Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)"

Lebwohl, M (via Mendeley Data)

September 2020

Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplem...

Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Lebwohl, M (via Mendeley Data)

September 2020

Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplem...

Supplementary Material for Shear et al.

Shear, N (via Mendeley Data)

March 2021

Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...

Supplemental Material, PRISMA_NMA_Checklist - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, PRISMA_NMA_Checklist for Guselkumab for the Treatment of Moderate-to-Severe P...

Supplementary Material for: Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions

Gerdes S. (4906354)
Krakor M. (4906348)
Anger T. (4906357)
Hutt H.J. (4906351)
Körber A. (4473115)

March 2018

Background/Aims: To assess the efficacy and tolerability of the new aerosol foam of ca...

Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.

Kerkhof, P.C.M. van de
Peuter, R. de
Ryttov, J.
Jansen, J.P.

January 2011

Item does not contain fulltextOBJECTIVE: The efficacy of the two-compound formulation (TCF) product ...

Supplemental Materials for Stein Gold et al. A Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Stein Gold, L

Mendeley Supplemental Tables and Figures for Stein Gold et al. A Phase 2b, Randomized Clinical Trial...

Supplemental Materials for Stein Gold et al. A Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Stein Gold, L (via Mendeley Data)

May 2020

Mendeley Supplemental Tables and Figures for Stein Gold et al. A Phase IIb, Randomized Clinical Tria...

Secondary Efficacy Outcomes from a Phase 2b, Randomized Dose-Finding Study of Tapinarof Cream for the Treatment of Plaque Psoriasis

Stein Gold, Linda F
Bhatia, N
Tallman, A M
Rubenstein, D

August 2019

Introduction: Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under inv...

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients with Mild to Moderate Plaque Psoriasis: Results of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial. J Am Acad Dermatol. 2021.

Stein Gold, L

Mendeley Supplemental Figures and Table for Stein Gold et al. Efficacy and Safety of Apremilast in P...

34613 Tapinarof cream 1% once daily (QD) for plaque psoriasis: Secondary efficacy outcomes from a long-term extension (LTE) trial

Stein Gold, Linda F
Ehst, Benjamin
Ferris, Laura K
Brown, Philip M
Rubenstein, David S
Tallman, Anna M
Bagel, Jerry

September 2022

Background: Tapinarof cream 1% QD was efficacious and well tolerated versus vehicle in adults with m...

Supplementary Appendix - Efficacy and Patient-Reported Outcomes from a Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis

Paller, A (via Mendeley Data)

August 2020

Mendeley Supplemental Tables and Figures for Paller A, et al. Efficacy and Patient-Reported Outcomes...

SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial

Strober, B

Supplementary materials for the publication of Strober B. Deucravacitinib versus placebo and apremil...

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials

Desai, Seemal R
Stein Gold, Linda F
Cameron, Michael C
Golant, Alexandra
Lewitt, G. Michael
Bruno, Matthew J
Martin, George
Brown, Philip M
Rubenstein, David S
Butners, Victoria
Tallman, Anna M

October 2023

Tapinarof cream 1% (VTAMA(®); Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbo...

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...

Lebwohl, Mark (2020), Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)"

Lebwohl, M (via Mendeley Data)

September 2020

Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplem...

Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Lebwohl, M (via Mendeley Data)

September 2020

Supplementary material A presents the trial design and interventions of the PSO-LONG trial. Supplem...

Supplementary Material for Shear et al.

Shear, N (via Mendeley Data)

March 2021

Supplemental material for the manuscript, "Comparative Safety and Benefit-Risk Profile of Biologics ...

Supplemental Material, PRISMA_NMA_Checklist - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, PRISMA_NMA_Checklist for Guselkumab for the Treatment of Moderate-to-Severe P...

Supplementary Material for: Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions

Gerdes S. (4906354)
Krakor M. (4906348)
Anger T. (4906357)
Hutt H.J. (4906351)
Körber A. (4473115)

March 2018

Background/Aims: To assess the efficacy and tolerability of the new aerosol foam of ca...

Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.

Kerkhof, P.C.M. van de
Peuter, R. de
Ryttov, J.
Jansen, J.P.

January 2011

Item does not contain fulltextOBJECTIVE: The efficacy of the two-compound formulation (TCF) product ...

Supplemental Materials for Stein Gold et al. A Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. J Am Acad Dermatol. 2020.

Abstract

Extracted data

Related items

Related items